YOLFTbeta
China SXT Pharmaceuticals Inc

China SXT Pharmaceuticals Inc

SXTC · NASDAQ · Healthcare / Drug Manufacturers - Specialty & Generic

3.00USD+0.27 (+9.89%)

Price History

Full chart

Market Stats

Previous Close2.73
Open2.90
Day Range2.81 – 3.44
52-Week Range0.0383 – 300.00
Volume228.10K
Market Cap3.33M
P/E (TTM)0.00
Forward P/E0.00
EPS-730.40
Dividend Yield0.00%
Beta1.84
50-Day Avg15.22
200-Day Avg2,045.95

About

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers Advanced TCMP, including Directly-Oral-TCMP, and After-Soaking-Oral TCMP; Fine TCMP and Regular TCMP products; and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company serves pharmaceutical companies, chain pharmacies, and hospitals, as well as pharmaceutical distributors. China SXT Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Taizhou, China.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Feng Zhou
  • Employees56
  • Headquarters178 Taidong Road North, Taizhou, China, 225300, USA
  • Websitehttps://www.sxtchina.com

Leadership

  • Mr. Feng ZhouChairman of the Board & Co-CEO · b. 1992
  • Mr. Sze Beng LimCo-Chief Executive Officer · b. 1977
  • Mr. Xiaodong PanChief Financial Officer · b. 1977
  • Mr. Jun ZhengExecutive Director · b. 1976

Financials

Income Statement

Currency: USD2016-03-312017-03-312018-03-312019-03-312020-03-312021-03-312022-03-312023-03-312024-03-312025-03-312026-03-31
Total Revenue3.72M4.88M7.02M7.01M5.16M4.78M2.60M1.97M1.93M1.74M1.07M
Growth (%)-+31.27%+43.79%-0.10%-26.38%-7.45%-45.53%-24.23%-2.19%-9.73%-38.39%
Cost of Revenue2.92M2.57M3.62M2.40M2.46M1.94M1.35M1.55M1.37M1.37M889.35K
Gross Profit793.99K2.31M3.40M4.61M2.70M2.84M1.25M426.27K553.97K367.43K183.28K
Gross Margin21.35%47.36%48.46%65.77%52.37%59.43%48.10%21.62%28.73%21.11%17.09%
Operating Expense584.85K709.82K1.77M2.84M4.04M5.04M6.44M6.03M3.07M3.05M7.31M
Operating Income209.14K1.60M1.63M1.77M-1.34M-2.20M-5.19M-5.61M-2.52M-2.68M-7.12M
Operating Margin5.62%32.82%23.25%25.24%-25.98%-45.99%-199.43%-284.40%-130.42%-153.97%-664.06%
EBITDA298.11K1.70M1.76M1.98M-1.01M-1.85M-5.05M-5.21M-2.35M-2.57M-6.98M
EBITDA Margin8.02%34.85%25.10%28.20%-19.55%-38.76%-194.11%-264.13%-121.91%-147.80%-650.71%
Net Income141.54K1.19M1.19M1.54M-10.29M-2.75M-5.74M-5.93M-3.10M-3.30M-6.21M
Net Income Margin3.81%24.28%16.92%21.95%-199.29%-57.52%-220.43%-301.00%-160.67%-189.77%-578.49%
R&D--------184.19K191.39K178.76K
R&D as % of Total Revenue--------9.55%10.99%16.67%
Interest Expense51.06K40.39K7795.17K3.35M1.62M36.70K476.78K544.28K648.22K62.97K
Interest Expense % of Total Revenue1.37%0.83%0.01%0.07%64.87%33.81%1.41%24.18%28.22%37.23%5.87%

Balance Sheet

Currency: USD2016-03-312017-03-312018-03-312019-03-312020-03-312021-03-312022-03-312023-03-312024-03-312025-03-312026-03-31
Total Assets6.30M5.43M7.66M17.47M21.70M34.55M33.55M29.55M23.13M21.66M34.75M
Total Liabilities5.55M3.58M4.37M6.36M12.30M18.59M17.12M14.86M9.20M6.22M5.05M
Total Equity742.77K1.85M3.29M11.11M9.40M15.96M16.42M14.69M13.93M15.44M29.71M
Cash11.44K65.57K560.25K9.13M7.29M13.33M15.52M17.37M12.07M18.10M28.18M
Total Debt479.23K302.17K385.12K2.79M6.72M43.41K10.74M3.76M2.65M983.88K1.12M
Net Debt467.79K236.60K-175.13K-8.87M-563.16K-13.29M-4.78M-13.61M-9.42M-17.12M-27.06M

Cash Flow

Currency: USD2016-03-312017-03-312018-03-312019-03-312020-03-312021-03-312022-03-312023-03-312024-03-312025-03-312026-03-31
Operating Cash Flow182.47K293.04K1.92M239.19K934.25K-1.32M-2.37M-80.76K-1.93M-2.35M-4.02M
Investing Cash Flow-95.76K-186.31K-1.14M-610.09K-5.50M-5.81M-46.91K-12.30K26.42K63.52K-1.25M
Financing Cash Flow-128.59K-50.56K-314.22K9.04M3.02M12.41M1.63M2.94M-2.62M8.40M14.43M
Capital Expenditure96.99K186.31K1.05M610.09K406.66K93.04K62.49K70.68K7.06K2.02K4
Free Cash Flow85.48K106.73K869.44K-370.89K527.59K-1.41M-2.44M-151.44K-1.94M-2.35M-4.02M
Dividends Paid---2.38M-------
FCF to OCF46.85%36.42%45.28%-155.06%56.47%107.07%102.63%187.53%100.37%100.09%100.00%
Dividend Paid to FCF----642.47%-------

Earnings

Report DateMar 31, 2017Jun 30, 2017Sep 30, 2017Mar 31, 2018May 7, 2018Sep 30, 2018Oct 3, 2018Mar 28, 2019Jun 30, 2019Aug 15, 2019Dec 31, 2019Mar 31, 2020Apr 22, 2020Jul 31, 2020Dec 31, 2020Jan 28, 2021Aug 13, 2021Jan 14, 2022Jul 18, 2022Mar 28, 2025Jul 31, 2025Dec 31, 2025Oct 7, 2026
EPS Estimate0.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.00-
EPS Actual0.070.080.080.040.040.100.010.05-0.210.07-0.59-0.59-0.10-0.42-0.130.10-0.27-0.20-2.03-1.99-1.02-0.05-
Surprise-----------------------
Timing-----------------------

Key Statistics & Ratios

Market Cap3.33M
Enterprise Value-23.74M
Trailing P/E0.00
Forward P/E0.00
Price / Sales2.93
Price / Book0.11
EPS-730.40
Book Value2,480.58
Revenue (TTM)1.14M
Gross Profit (TTM)248.70K
EBITDA-7.05M
Profit Margin0.00%
Operating Margin-153.28%
Return on Equity-27.49%
Return on Assets-15.78%
Shares Outstanding1.32M
Shares Float401.68K
Beta1.84
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Ownership Breakdown

Institutions
0.00%
Insiders
33.37%
Retail / Other
66.63%

Top Institutional Holders

  • Sabby Management LLC
    78.17K0.20%
  • Caitong International Asset Management Co., Limited.
    10.00%
  • UBS Group AG
    10.00%
  • Amvescap Plc.
    00.00%
  • Geode Capital Management, LLC
    00.00%
  • Tower Research Capital LLC
    00.00%
  • Citadel Advisors Llc
    00.00%
  • Royal Bank of Canada
    130.00%

Top Fund Holders

  • Fidelity Nasdaq Composite Index
    3560.00%

Stock Splits

  • Oct 26, 20261:100
  • Aug 10, 20261:80
  • Feb 3, 20261:150
  • Oct 5, 20231:25
  • Feb 22, 20211:4